ALX Oncology to Present at Upcoming Investor Conferences in September
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences.
The details of the meetings are as follows:
Wells Fargo 21st Annual Healthcare Conference
Format: Fireside Chat and One-on-one Meetings
Date: Wednesday, September 9, 2026
Location: Boston, MA
Time of Fireside Chat Presentation: 3:45 PM ET
Webcast link: Available here
Cantor Global Healthcare Conference
Format: Fireside Chat and One-on-one Meetings
Date: Thursday, September 10, 2026
Location: New York, NY
Time of Fireside Chat Presentation: 10:20 AM ET
Webcast link: Available here
H.C. Wainwright 28th Annual Global Investment Conference
Format: Fireside Chat and One-on-one Meetings
Date: Monday, September 14, 2026
Location: New York, NY
Time of Fireside Chat Presentation: 1:30 PM ET
Webcast link: Available here
The webcasts of the fireside chats can be accessed through the links above or by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com under the Events section of the Events and Presentations tab. Replays of the webcasts will be archived for up to 90 days following the presentation dates.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn.
Investor Relations Contact:
Kevin Lui
Director, Investor Relations
kevin.lui@precisionaq.com
Media Contact:
Genevieve Britton
Senior Director, Public Relations
genevieve.britton@precisionaq.com
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
Why This Vanguard ETF Is One of the Best
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
United States